Jubilant Pharmova gets [ICRA]AA+ (Stable) rating for ₹1,400 crore NCDs
Jubilant Pharmova Limited's proposed ₹1,400 crore non-convertible debentures have been assigned an [ICRA]AA+ (Stable) credit rating by ICRA Limited. The rating was confirmed on October 13, 2026.
The assignment of a high credit rating for a substantial debt issuance of ₹1,400 crore is a material event that can impact the company's borrowing costs and investor confidence, thus having a high impact.
A high credit rating ([ICRA]AA+) on a significant debt issuance (₹1,400 crore) indicates strong financial health and creditworthiness, which is positive for the company.
Jubilant Pharmova Limited has announced that ICRA Limited has assigned a credit rating of [ICRA]AA+ (Stable) to its proposed non-convertible debentures (NCDs) worth ₹1,400 crore.
The rating action was communicated by ICRA Limited on October 13, 2026, and received by the company on October 13, 2026, at 5:09 p.m. IST. This disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The rating is valid for the entire life of the NCD program until withdrawn. ICRA reserves the right to review or revise the rating based on new information or circumstances that may impact the company's debt servicing capability. The company has also made this disclosure available on its official website, www.jubilantpharmova.com.
What to do with a filing like this
Jubilant Pharmova Limited filed this with the NSE as a statutory disclosure, categorised under debt fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Pharmova Limited. Read the original for the full detail.